Budget Impact Analysis of Gemtuzumab Ozogamicin for the Treatment of CD33-Positive Acute Myeloid Leukemia

BACKGROUND: Gemtuzumab ozogamicin (GO) was approved in 2017 in the US for the treatment of adults with newly diagnosed CD33-positive (CD33+) acute myeloid leukemia (AML), and adults and pediatric patients with CD33+ relapsed/refractory (R/R) AML. OBJECTIVE: The aim of this study was to estimate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Mamolo, Carla, Welch, Verna, Walter, Roland B., Cappelleri, Joseph C., Brockbank, James, Cawson, Matthew, Knight, Chris, Wilson, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790788/
https://www.ncbi.nlm.nih.gov/pubmed/33236329
http://dx.doi.org/10.1007/s40273-020-00976-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790788/
https://www.ncbi.nlm.nih.gov/pubmed/33236329
http://dx.doi.org/10.1007/s40273-020-00976-6

Ejemplares similares